Sterne Agee Reiterates Buy Rating on MedAssets Following Tenet/Vanguard Announcement
In a report published Monday, Sterne Agee analyst Greg T. Bolan reiterated a Buy rating and $24.00 price target on MedAssets (NASDAQ: MDAS).
In the report, Sterne Agee noted, “This morning, Tenet Healthcare (THC, NR, $41.85) announced its intent to acquire Vanguard Health (VHS, NR, $12.37). We believe THC is MedAssets' largest client and that this acquisition represents potential new revenues to MedAssets, especially within the GPO business. MDAS remains our top pick within the HCIT industry; reiterate Buy rating and $24 PT.”
MedAssets closed on Friday at $17.59.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.